Guaifenesin
- CAS No.
- 93-14-1
- Chemical Name:
- Guaifenesin
- Synonyms
- GLYCERYL GUAIACOLATE;GUAIPHENESIN;3-(2-methoxyphenoxy)propane-1,2-diol;gge;XL-90;Robitussin;RAC GUAIFENESIN;Glyceryl guaiacyl ether;GUAIACOL GLYCEROL ETHER;Glyceryl guaiacolate ether
- CBNumber:
- CB1743199
- Molecular Formula:
- C10H14O4
- Molecular Weight:
- 198.22
- MOL File:
- 93-14-1.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/24 17:31:20
| Melting point | 77-81 °C |
|---|---|
| Boiling point | 215 °C (19 mmHg) |
| Density | 1.1825 (rough estimate) |
| refractive index | 1.5550 (estimate) |
| Flash point | 215°C/19mm |
| storage temp. | 2-8°C |
| solubility | 50g/l (experimental) |
| pka | 13.53±0.20(Predicted) |
| form | Solid |
| color | White to Off-White |
| Water Solubility | 5 g/100 mL (25 ºC) |
| Merck | 14,4555 |
| BRN | 2049375 |
| InChIKey | HSRJKNPTNIJEKV-UHFFFAOYSA-N |
| LogP | 1.390 |
| CAS DataBase Reference | 93-14-1(CAS DataBase Reference) |
| NIST Chemistry Reference | 3-(O-methoxyphenoxy)-1,2-propanediol(93-14-1) |
| EPA Substance Registry System | Guaifenesin (93-14-1) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P264-P270-P301+P312-P501 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22-36/37/38 | |||||||||
| Safety Statements | 26-36 | |||||||||
| WGK Germany | 1 | |||||||||
| RTECS | TY8400000 | |||||||||
| Hazard Note | Harmful | |||||||||
| TSCA | Yes | |||||||||
| HS Code | 29093090 | |||||||||
| Toxicity | LD50 oral in rabbit: 2553mg/kg | |||||||||
| NFPA 704 |
|
Guaifenesin price More Price(8)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | G5627 | Guaiacol glyceryl ether ≥98% (GC) | 93-14-1 | 25G | ₹2478.93 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1027 | Guaifenesin certified reference material, pharmaceutical secondary standard | 93-14-1 | 1G | ₹8356.9 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | G5627 | Guaiacol glyceryl ether ≥98% (GC) | 93-14-1 | 500G | ₹14440.55 | 2022-06-14 | Buy |
| ALFA India | ALF-A16827-30 | 3-(2-Methoxyphenoxy)-1,2-propanediol, 99+% | 93-14-1 | 250g | ₹5839 | 2022-05-26 | Buy |
| TCI Chemicals (India) | G0159 | Guaiacol Glycerol Ether | 93-14-1 | 25G | ₹2000 | 2022-05-26 | Buy |
Guaifenesin Chemical Properties,Uses,Production
Description
Guaifenesin is an oral expectorant drug. The expectorant action of guaifenesin is mediated by stimulation of the gastrointestinal tract. It is a common ingredient in prescription and over-the-counter medications used to treat cough due to colds and minor upper respiratory infections. Additionally, Guaifenesin is also a centrally-acting muscle relaxant and is used routinely in combination with analgesics and sedatives in large-animal veterinary surgery.
Chemical Properties
This substance is a white crystalline powder with a melting point of 78.5-79°C and a boiling point of 215°C (2.53kPa). It is soluble in 20ml of water and ethanol, chloroform, glycerin, and dimethylformamide. It is easily soluble in benzene but insoluble in petroleum ether. It has a slightly bitter taste and a slightly particular odor.
History
Guaifenesin was originally derived from the guaiac tree and used by Native Americans for health purposes. Synthesis of guaifenesin was first reported in 1912. Guaifenesin has been used in the treatment of respiratory diseases since the nineteenth century. The United States’ Food and Drug Administration (FDA) approved guaifenesin for use in overthe- counter medications in 1989. Guaifenesin is widely consumed alone and combined with antihistamines, cough suppressants, and decongestants. Guaifenesin is also a centrally acting muscle relaxant and is used routinely in combination with analgesics and sedatives in large-animal veterinary surgery.
Uses
Guaifenesin is a muscle relaxant with expectorant properties often used as an expectorant to facilitate the removal of phlegm from the airways in acute respiratory tract infections. Guaifenesin comes in tablet and capsule form, as syrup, as dissolving granules, and recently as an extended-release (longacting) tablet. The tablets, capsules, dissolving granules, and syrup are usually taken with or without food every 4 h as needed. The extended-release tablet is usually taken with or without food every 12 h.
General Description
Guaifenesin is an expectorant, widely used in the treatment of cough. Its mode of action involves the alleviating of cough discomfort by increasing sputum volume and decreasing its viscosity, thus resulting in effective cough.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Mechanism of action
Guaiphenesin facilitates secretion from bronchial mucous membranes, thus relieving a cough in colds, bronchitis, and bronchial asthma.
Environmental Fate
Guaifenesin’s production and use as veterinary and human
medicines may result in its release to the environment through
various waste streams.
If released to air, an estimated vapor pressure of
1.5× 10–6 mm Hg at 25 ℃ indicates that guaifenesin will
exist in both the vapor and particulate phase.
Based upon an estimated Henry’s law constant of
4.4 × 10-11 atm-m3 mol-1, volatilization from moist soil
surfaces or from water surfaces are not expected to be important
fate processes for guaifenesin.
Guaifenesin is expected to have high mobility in soil based
upon an organic carbon–water partition coefficient (Koc) of
140, which indicates that it will have more solubility in water
and is less likely to adsorb onto organic matter in soil and
plants.
References
[1] Peter V. Dicpinigaitis and Yvonne E. Gayle, Effect of Guaifenesin on Cough Reflex Sensitivity, 2003, vol. 124, 2178-2181 DOI:10.1378/CHEST.124.6.2178
[2] Leonid Kagan, Eran Lavy and Ammon Hoffmann, Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model, Pulmonary Pharmacology & Therapeutics, 2009, vol. 22, 260-265 DOI:10.1016/j.pupt.2008.12.020
[3] Sittig's Pharmaceutical Manufacturing Encyclopedia
[4] Synthesis of Essential Drugs (2006, Elsevier)
[5] Plumb's Veterinary Drug Handbook
[6] https://pubchem.ncbi.nlm.nih.gov/compound/Guaifenesin
Guaifenesin Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| THE MOLECULEZ | +91-7506703683 +91-7506703683 | Maharashtra, India | 79 | 58 | Inquiry |
| Unilab Company | +91-912228260263 +91-63917864522 | Tamil Nadu, India | 43 | 58 | Inquiry |
| Frolic Pharmachem | +919711094561 | Himachal Pradesh, India | 94 | 58 | Inquiry |
| GLP Pharma Standards | +91 9866074638 | Hyderabad, India | 1644 | 58 | Inquiry |
| KARPSCHEM LABORATORIES | +91-7249203006 +91-7249203006 | Maharashtra, India | 786 | 58 | Inquiry |
| Medi Pharma Drug House | +919930911911 | Mumbai, India | 143 | 58 | Inquiry |
| Gennex Laboratories Limited | +91-9346516012 +91-9346516012 | Hyderabad, India | 11 | 58 | Inquiry |
| Synthokem Labs Private Limited | +91-9966400646 +91-9966400646 | Hyderabad, India | 15 | 58 | Inquiry |
| Smilax Laboratories Limited | +91-8919514965 +91-8008333438 | Telangana, India | 28 | 58 | Inquiry |
| S S Pharmachem | +91-9324209894 +91-9702111022 | Maharashtra, India | 20 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| THE MOLECULEZ | 58 |
| Unilab Company | 58 |
| Frolic Pharmachem | 58 |
| GLP Pharma Standards | 58 |
| KARPSCHEM LABORATORIES | 58 |
| Medi Pharma Drug House | 58 |
| Gennex Laboratories Limited | 58 |
| Synthokem Labs Private Limited | 58 |
| Smilax Laboratories Limited | 58 |
| S S Pharmachem | 58 |
93-14-1(Guaifenesin)Related Search:
1of4
chevron_right